Advertisement Medtronic unit to pay $75 million to settle Medicare fraud case - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Medtronic unit to pay $75 million to settle Medicare fraud case

Medtronic has announced that Kyphon has signed a final settlement agreement with the US Department of Justice. This settlement agreement formalizes the resolution reached by Kyphon, prior to its acquisition by Medtronic, of a 2005 civil qui tam action filed against Kyphon in the Western District of New York.

The settlement requires Kyphon to pay $75 million plus accrued interest to the US, to settle allegations relating to reimbursement advice that the company gave to customers regarding kyphoplasty procedures. The settlement agreement reflects the company’s assertion that Kyphon and its employees had not engaged in any wrongdoing or illegal activity.

In addition to the payment, Kyphon will enter into a corporate integrity agreement (CIA) with the Office of Inspector General for the Department of Health and Human Services. The CIA focuses on training about appropriate reimbursement advice to customers, and also requires maintenance and implementation of standard compliance processes.

The settlement amount had been reserved on Kyphon’s books prior to the closing of the acquisition by Medtronic; therefore Medtronic will not be incurring a charge related to this settlement.